Polyclonal Antibodies Global Market Report 2024

The polyclonal antibodies market has grown strongly in recent years. It will grow from $1.35 billion in 2023 to $1.43 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth observed in the historic period can be primarily attributed to several key factors. There was a notable surge in demand for biomedical research, driving advancements in the field. Additionally, increased utilization across diagnostic applications significantly contributed to this growth. The rise in chronic diseases heightened the need for effective solutions, leading to an expanded use of these technologies across a wide spectrum of applications. Overall, this period saw an increased recognition and utilization of these technologies owing to their versatility and adaptability across various domains.

The polyclonal antibodies market is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2028 at a compound annual growth rate (CAGR) of 6.4%. Anticipated growth in the forecast period is expected to be fueled by several key factors. The expansion of diagnostic technologies and therapeutic advancements will likely play pivotal roles in driving this growth trajectory. The rise in infectious diseases is also anticipated to contribute significantly to the increased demand for these technologies. Furthermore, the forecasted period is projected to witness a surge in research funding and an increase in collaborations and partnerships, further propelling growth in this sector.

The anticipated rise in cancer cases is poised to drive the expansion of the polyclonal antibodies market. These antibodies play a pivotal role in cancer research and treatment, aiding in biomarker detection, targeted therapy, and immunotherapy. Notably, the escalating instances of stomach cancer in Australia in 2022, projected by Cancer Australia, underscore the market's growth potential. The surge in cancer diagnoses significantly contributes to the demand for polyclonal antibodies, enhancing cancer diagnosis and treatment methodologies.

The surge in infectious disease outbreaks is anticipated to fuel the growth of the polyclonal antibodies market. These antibodies are crucial in understanding and managing infectious diseases due to their versatility and specificity. Highlighting this trend, the Centers for Disease Control and Prevention's report in March 2023 outlined an increase in tuberculosis cases in the United States. This escalation in infectious diseases emphasizes the essential role of polyclonal antibodies in combating such health crises.

Research and development emerge as a prominent trend driving the polyclonal antibodies market. Leading companies are actively engaged in R&D endeavors to enhance their efficacy and maintain market leadership. For instance, GigaGen Inc.'s July 2022 publication showcases their pioneering work on GIGA-2050, a recombinant polyclonal product targeting SARS-CoV-2. This innovative product, derived from a single master cell bank containing over 12,000 antibodies, signifies a significant leap in manufacturing recombinant polyclonal antibodies, surpassing prior industry standards.

Strategic partnerships form a cornerstone strategy for major players in the polyclonal antibodies market. Companies leverage collaborative alliances to optimize resources and capabilities for mutual benefit. An exemplar is the partnership announced in October 2022 between SAB Biotherapeutics and Emergent BioSolutions, Inc. This collaboration entails Emergent providing manufacturing services to SAB for clinical investigational medications and potential commercial manufacturing. Additionally, the agreement allows Emergent access to SAB's advanced DiversitAb technology for future product development, leveraging fully human polyclonal antibodies using transchromosomic cows.

In February 2022, Rockland Immunochemical Inc., a US-based company known for its development of antibody-based assays and research tools, completed the acquisition of Antibodies-Online GmbH. This undisclosed investment allows Rockland to integrate expertise in antibody design, development, and manufacturing. The acquisition notably capitalizes on Antibodies-Online GmbH's esteemed e-commerce brand, extensive supplier network, and proprietary antibody-online technology stack. Notably, Antibodies-Online GmbH, based in Germany, is recognized for its provision of high-quality, specifically-targeted polyclonal primary antibodies.

Major companies operating in the polyclonal antibodies market report are Abcam plc, GenScript Biotech Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Creative Diagnostics, Agilent Technologies, Analytik Jena GmbH, Atlas Antibodies, Danaher Corporation, DC Biosciences Ltd., Illumia Inc., ImmonoPresice Antibodies Ltd., Fujirebio, Omega BioTek Inc., Dovetail Genomics LLC, Abnova Corporation, Santa Cruz Biotechnology Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., IGY Life Sciences, Genway Biotech, Good Biotech, Gallus Immunotech Inc., BioGenes GmbH, Capralogics Inc., Bio X Cell.

North America was the largest region in the polyclonal antibodies market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global polyclonal antibodies market size forecast period. The regions covered in the polyclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the polyclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary and secondary antibodies constitute the main products derived from polyclonal antibodies. A primary antibody within this polyclonal mixture binds specifically to the target antigen, playing a pivotal role in various applications. These applications span immunohistochemistry, Western blotting, ELISA, and an array of immunological assays. The sources of polyclonal antibodies typically include rabbits, goats, sheep, and other animals, serving purposes in research, diagnostics, and therapeutic endeavors across academic institutions, research centers, pharmaceutical and biotech firms, diagnostic facilities, and hospitals.

The polyclonal antibodies market research report provides polyclonal antibodies market statistics, including polyclonal antibodies industry global market size, regional shares, competitors with a polyclonal antibodies market share, detailed polyclonal antibodies market segments, market trends, and opportunities, and any further data you may need to thrive in the polyclonal antibodies industry. This polyclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The polyclonal antibodies market consists of sales of anti-cd4 polyclonal antibodies, anti-her2 polyclonal antibodies, and anti-insulin polyclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.